DTU Publications (2010-2019)
2019
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A. et al, (2019), Circ Cardiovasc Interv, 12
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
Bhatt AS. et al, (2019), Am Heart J, 218, 57 - 65
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
Bethel MA. et al, (2019), Diabetes Care, 42, 1075 - 1080
Diabetes Care Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and Care.
Riddle MC. et al, (2019), Diabetes Care, 42, 1136 - 1146
Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163.
Standl E. et al, (2019), Diabetes Care, 42
Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC).
Rahimi K. et al, (2019), BMJ Open, 9
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study.
McGovern AP. et al, (2019), BMC Med, 17
Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes.
Harrison P. et al, (2019), Platelets, 30, 521 - 529
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE. et al, (2019), Diabetes Care, 42, 318 - 326
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.
Fanaroff AC. et al, (2019), Circulation, 139, 863 - 873
Real-world studies no substitute for RCTs in establishing efficacy.
Gerstein HC. et al, (2019), Lancet, 393, 210 - 211
Progression of glucose-lowering diabetes therapy in TECOS.
Bethel MA. et al, (2019), Endocrinol Diabetes Metab, 2
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M. et al, (2019), Circulation, 140, 1613 - 1622
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials.
Czernichow S. et al, (2011), J Hypertens, 29, 4 - 16
Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Coleman RL. et al, (2019), Cardiovasc Diabetol, 18
A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health.
Moolla A. et al, (2019), Frontline Gastroenterol, 10, 337 - 346
The importance of randomised vs non-randomised trials - Authors' reply.
Gerstein HC. et al, (2019), Lancet, 394
Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.
Guimarães PO. et al, (2019), Int J Cardiol, 289, 58 - 62
2018
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Dennis JM. et al, (2018), Diabetes Care, 41, 705 - 712
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.
Mentz RJ. et al, (2018), Circulation, 138, 2576 - 2578
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E. et al, (2018), Diabetes Care, 41, 596 - 603
Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.
Holman RR., (2018), Nat Rev Endocrinol, 14, 67 - 68
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA. et al, (2018), Lancet Diabetes Endocrinol, 6, 105 - 113
Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.
Mostafa SA. et al, (2018), Diabet Med, 35, 72 - 77
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
Cefalu WT. et al, (2018), Diabetes Care, 41, 14 - 31
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J. et al, (2018), Diabetes Obes Metab, 20, 2379 - 2388
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Davis TME. et al, (2018), Diabetes Obes Metab, 20, 1427 - 1434
Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL
Mentz RJ. et al, (2018), EUROPEAN HEART JOURNAL, 39, 1082 - 1082
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
Dennis JM. et al, (2018), Diabetes Care, 41, 1844 - 1853
What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?
Holman RR., (2018), J Diabetes, 10, 683 - 685
Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial.
Kraus WE. et al, (2018), BMJ Open Diabetes Res Care, 6
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD. et al, (2018), Diabetes Obes Metab, 20, 1732 - 1739
Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.
Lim LL. et al, (2018), Diabetes Care, 41, 1312 - 1320
A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.
Riddle MC. et al, (2018), Diabetes Care, 41, 1121 - 1124
Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.
Griffin SJ. et al, (2018), Health Technol Assess, 22, 1 - 64
2017
Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
Theodorakis MJ. et al, (2018), Am Heart J, 199, 170 - 175
Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.
Malhotra R. et al, (2017), JAMA Intern Med, 177, 1498 - 1505
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Preiss D. et al, (2017), Diabetes Obes Metab, 19, 356 - 363
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Engel SS. et al, (2017), Diabetes Obes Metab, 19, 1587 - 1593
Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.
Navar AM. et al, (2017), Hypertension, 70, 907 - 914
Health selection into neighborhoods among patients enrolled in a clinical trial.
Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Sharma A. et al, (2017), Diabetes Care, 40, 1763 - 1770
Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR. et al, (2017), N Engl J Med, 377
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR. et al, (2017), N Engl J Med, 377, 1228 - 1239
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ. et al, (2017), Circulation, 136, 1193 - 1203
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Mentz RJ. et al, (2017), Am Heart J, 187, 1 - 9
Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB. et al, (2017), Diabetes Care, 40, 164 - 170
Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?
Paul SK. and Holman RR., (2017), Diabet Med, 34, 1284 - 1290
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Harumi Higuchi Dos Santos M. et al, (2017), J Am Heart Assoc, 6
Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T).
Levy JC. et al, (2017), Diabetes Res Clin Pract, 131, 161 - 168
Microvascular outcomes in type 2 diabetes - Authors' reply.
Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5, 431 - 437
Corrections needed to 2016 ESC and AHA guidelines on heart failure.
Rydén L. et al, (2017), Lancet Diabetes Endocrinol, 5, 325 - 326
Updated risk factors should be used to predict development of diabetes.
Bethel MA. et al, (2017), J Diabetes Complications, 31, 859 - 863
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA. et al, (2017), Diabetes Care, 40, 494 - 501
2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
Blom DJ. et al, (2017), Diabetes Obes Metab, 19, 98 - 107
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH. et al, (2016), Diabetes Care, 39, 2304 - 2310
Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database.
Farmer AJ. et al, (2016), Diabetes Care, 39, 258 - 263
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Bethel MA. et al, (2016), Diabet Med, 33, 224 - 230
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study.
Preiss D. et al, (2016), Diabet Med, 33, 1569 - 1574
The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: A cluster randomised sub-study.
Farmer AJ. et al, (2016), Diabetes Res Clin Pract, 120, 56 - 64
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.
Zhou K. et al, (2016), Nat Genet, 48, 1055 - 1059
Preface - Diabetes prevention and management.
Holman RR., (2016), Best Pract Res Clin Endocrinol Metab, 30
This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
Ryder REJ. et al, (2016), British Journal of Diabetes and Vascular Disease, 16, 88 - 92
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK. et al, (2016), JAMA Cardiol, 1, 126 - 135
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR. et al, (2016), International Journal of Endocrinology and Metabolism, 36
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR. et al, (2016), Am Heart J, 174, 103 - 110
2015
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Preiss D. et al, (2015), BMJ Open, 5
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR. and Peterson ED., (2015), N Engl J Med, 373
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.
Blood Pressure Lowering Treatment Trialists' Collaboration None. et al, (2015), Lancet, 385, 867 - 874
The effect of glibenclamide on insulin secretion at normal glucose concentrations
Riefflin A. et al, (2015), Diabetologia, 58, 43 - 49
Physical activity as a determinant of fasting and 2-h post-challenge glucose: A prospective cohort analysis of the NAVIGATOR trial
Yates T. et al, (2015), Diabetic Medicine, 32, 1090 - 1096
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB. et al, (2015), N Engl J Med, 373, 232 - 242
The University of Oxford Diabetes Trials Unit.
Holman R. and Nicholls M., (2015), Eur Heart J, 36, 1706 - 1707
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]
Levy JC. et al, (2015), Diabetologia, 58, 1376 - 1377
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR. et al, (2016), International Journal of Endocrinology and Metabolism, 36
Normal weight individuals who develop type 2 diabetes: the personal fat threshold.
Taylor R. and Holman RR., (2015), Clin Sci (Lond), 128, 405 - 410
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Bethel MA. et al, (2015), Diabetes, Obesity and Metabolism, 17, 395 - 402
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
Alva ML. et al, (2015), Diabet Med, 32, 459 - 466
2014
Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
de Barros e Silva PGM. et al, (2014), Int J Cardiol, 176, 1126 - 1128
Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort: does the ADDITION validation add up?
Gray A. et al, (2014), Value Health, 17, 895 - 896
Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study
Preiss D. et al, (2014), Diabetes, Obesity and Metabolism, 16, 1265 - 1268
Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored
McMurray JJV. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 843 - 851
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
Holman RR. et al, (2014), Lancet, 384, 1097 - 1098
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2014), Lancet, 384, 591 - 598
Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus
Holman RR., (2014), Nature Reviews Endocrinology, 10, 453 - 454
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR. et al, (2016), International Journal of Endocrinology and Metabolism, 36
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
Holman RR. et al, (2014), Lancet, 383, 2008 - 2017
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
Huffman KM. et al, (2014), Metabolism: Clinical and Experimental, 63, 554 - 561
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
Yates T. et al, (2014), The Lancet, 383, 1059 - 1066
Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)
Davis TME. et al, (2014), Diabetic Medicine, 31, 200 - 207
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): A randomised controlled trial
Preiss D. et al, (2014), The Lancet Diabetes and Endocrinology, 2, 116 - 124
2013
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Green JB. et al, (2013), American Heart Journal, 166
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Latini R. et al, (2013), Am Heart J, 166, 935 - 40.e1
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D. et al, (2013), Stroke, 44, 2590 - 2593
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.
Hayes AJ. et al, (2013), Diabetologia, 56, 1925 - 1933
A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
Bethel MA. et al, (2013), Am J Cardiol, 112, 231 - 237
Evaluation of a self-administered oral glucose tolerance test.
Bethel MA. et al, (2013), Diabetes Care, 36, 1483 - 1488
Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.
Leal J. et al, (2013), Diabetes Care, 36, 1541 - 1546
Metformin and mortality. Reply to Lund SS [letter].
Stevens RJ. et al, (2013), Diabetologia, 56, 939 - 940
Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
Davis TME. et al, (2013), Circulation, 127, 980 - 987
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
Holman RR., (2013), Nature Reviews Endocrinology, 9, 67 - 68
2012
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
Stevens RJ. et al, (2012), Diabetologia, 55, 2593 - 2603
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
Mcmurray JJV. et al, (2012), Journal of Clinical Hypertension, 14, 731 - 731
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts
van Leeuwen N. et al, (2012), Diabetologia, 1 - 7
Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice
Price HC. et al, (2012), Practical Diabetes, 29, 61 - 64
Understanding the outcomes of multi-centre clinical trials: A qualitative study of health professional experiences and views
Lawton J. et al, (2012), Social Science and Medicine, 74, 574 - 581
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Punthakee Z. et al, (2012), Diabetologia, 55, 36 - 45
2011
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
Farmer AJ. et al, (2011), Diabetes Obes Metab, 13, 1136 - 1141
Incidence of diabetes following ramipril or rosiglitazone withdrawal
Holman RR. et al, (2011), Diabetes Care, 34, 1265 - 1269
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Lachin JM. et al, (2011), Clin J Am Soc Nephrol, 6, 1032 - 1040
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Kahn SE. et al, (2011), Diabetes, 60, 1552 - 1560
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration None., (2011), J Hypertens, 29, 623 - 635
2010
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group None. et al, (2011), Nat Genet, 43, 117 - 120
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial
Neil HAW. et al, (2010), Atherosclerosis, 213, 512 - 517
Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences.
Jenkins N. et al, (2010), Diabetes Care, 33, 2178 - 2180
Recommendations for biomarker identification and qualification in clinical proteomics.
Mischak H. et al, (2010), Sci Transl Med, 2
Life expectancy in individuals with type 2 diabetes: implications for annuities.
Price HC. et al, (2010), Med Decis Making, 30, 409 - 414
Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Reply to Wägner AM, Mauricio D [letter].
Farmer AJ. et al, (2010), Diabetologia
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H. et al, (2010), Cardiovasc Ther, 28, 124 - 132
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
NAVIGATOR Study Group None. et al, (2010), N Engl J Med, 362, 1463 - 1476
Effect of valsartan on the incidence of diabetes and cardiovascular events.
NAVIGATOR Study Group None. et al, (2010), N Engl J Med, 362, 1477 - 1490
Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
Kahn R. et al, (2010), Lancet, 375, 1365 - 1374
Insulin Regimens in Type 2 Diabetes REPLY
Holman RR. and Darbyshire JL., (2010), NEW ENGLAND JOURNAL OF MEDICINE, 362, 960 - 960
Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A. et al, (2010), Diabetes Care, 33, 252 - 257
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
Kahn SE. et al, (2010), Diabetes Care, 33, 177 - 183